{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:34:32Z","timestamp":1779183272138,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.dsx.2019.04.041","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T11:33:47Z","timestamp":1556019227000},"page":"1893-1896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Are SGLT2 inhibitors joining the mainstream therapy for diabetes type\u00a02?"],"prefix":"10.1016","volume":"13","author":[{"given":"Mortaza F.","family":"Hassanabad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra F.H.","family":"Abad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2019.04.041_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2019.04.041_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2015.03.004","article-title":"The role of sodium-glucose Co-transporter 2 inhibitors in the treatment of type 2 diabetes","author":"Whalen","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.dsx.2019.04.041_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis","author":"Baker","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.dsx.2019.04.041_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.dsx.2019.04.041_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","author":"Shyangdan","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.dsx.2019.04.041_bib6","doi-asserted-by":"crossref","DOI":"10.3810\/pgm.2014.01.2720","article-title":"Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor","author":"Nicolle","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.dsx.2019.04.041_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-016-4194-y","article-title":"The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects","author":"Vettor","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2019.04.041_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehx511","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOMEVR trial","author":"Fitchett","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2019.04.041_bib9","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2019.04.041_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCP.0000000000000392","article-title":"Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials","volume":"35","author":"Zheng","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.dsx.2019.04.041_bib11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/meta.2001.24192","article-title":"Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30","volume":"50","author":"Glueck","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.dsx.2019.04.041_bib12","article-title":"Diagnosis and classification of diabetes mellitus","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.04.041_bib13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM199602083340607","article-title":"Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system","volume":"334","author":"Reaven","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2019.04.041_bib14","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.105.563213","article-title":"Reciprocal relationships between insulin resistance and endothelial dysfunction","volume":"113","author":"Kim","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.dsx.2019.04.041_bib15","article-title":"Treatment of hypertension in adults with diabetes","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.04.041_bib16","doi-asserted-by":"crossref","DOI":"10.2174\/1381612823666170519144841","article-title":"Effects of oral and non-insulin injectable Antidiabetic treatment in hypertension: a systematic review","author":"Katsi","year":"2017","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.dsx.2019.04.041_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-018-0937-z","article-title":"Empagliflozin: a review in type 2 diabetes","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.dsx.2019.04.041_bib18","article-title":"Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus","author":"Li","year":"2017","journal-title":"Med (United States)"},{"key":"10.1016\/j.dsx.2019.04.041_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2981","article-title":"When metformin is not enough: pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy","author":"Avogaro","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"10.1016\/j.dsx.2019.04.041_bib20","first-page":"629","article-title":"Management of hyperglycaemia of type 2 diabetes. Paradigm change according to the ADA-EASD consensus report 2018","volume":"73","author":"Scheen","year":"2018","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.dsx.2019.04.041_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.14724","article-title":"Metformin-SGLT2, dehydration, and acidosis potential","author":"D'Elia","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.dsx.2019.04.041_bib22","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","author":"Johnsson","year":"2013","journal-title":"J\u00a0Diabet Complicat"},{"key":"10.1016\/j.dsx.2019.04.041_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/dme.13508","article-title":"Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes","author":"Kumar","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2019.04.041_bib24","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v10.i2.133","article-title":"Bilateral gangrene of fingers in a patient on empagliflozin: first case report","author":"Pai","year":"2019","journal-title":"World J Diabetes"},{"key":"10.1016\/j.dsx.2019.04.041_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/00325481.2018.1457397","article-title":"Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers","author":"Tong","year":"2018","journal-title":"Postgrad Med"},{"key":"10.1016\/j.dsx.2019.04.041_bib26","article-title":"Emerging treatments in type 2 diabetes: focus on canagliflozin","author":"Rosiak","year":"2014","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.dsx.2019.04.041_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ihj.2018.08.022","article-title":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","author":"Pancholia","year":"2018","journal-title":"Indian Heart J"},{"key":"10.1016\/j.dsx.2019.04.041_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2019.04.041_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose Co-Transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology","author":"Kalra","year":"2014","journal-title":"Diabet Ther"},{"key":"10.1016\/j.dsx.2019.04.041_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-016-0498-9","article-title":"Pharmacokinetic characteristics and clinical efficacy of an SGLT2 inhibitor plus DPP-4 inhibitor combination therapy in type 2 diabetes","author":"Scheen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dsx.2019.04.041_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-018-0943-5","article-title":"SGLT2 inhibitors and mechanisms of hypertension","author":"Briasoulis","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.dsx.2019.04.041_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-017-9666-8","article-title":"The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus","author":"Asleh","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.dsx.2019.04.041_bib33","doi-asserted-by":"crossref","DOI":"10.2147\/VHRM.S111991","article-title":"Impact of sodium\u2013glucose cotransporter 2 inhibitors on blood pressure","author":"Reed","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.dsx.2019.04.041_bib34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00125-017-4479-9","article-title":"Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans","volume":"61","author":"Loh","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2019.04.041_bib35","doi-asserted-by":"crossref","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2019.04.041_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/nrneph.2017.182","article-title":"Diabetic kidney disease in 2017: a new era in therapeutics for diabetic kidney disease","author":"Wanner","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.dsx.2019.04.041_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-016-0379-5","article-title":"Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review","author":"Kalra","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.dsx.2019.04.041_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.dsx.2019.04.041_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2019.04.041_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the european society of Cardiology","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.dsx.2019.04.041_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2019.04.041_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/nrcardio.2017.211","article-title":"Effect of glucose-lowering therapies on heart failure","author":"Nassif","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.dsx.2019.04.041_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2018.05.028","article-title":"The place of gliclazide MR in the evolving type 2 diabetes landscape: a comparison with other sulfonylureas and newer oral antihyperglycemic agents","author":"Colagiuri","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2019.04.041_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40842-018-0061-8","article-title":"Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study","volume":"4","author":"Ghosal","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2019.04.041_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjd.2017.01.009","article-title":"Considerations for initiating a sodium-glucose Co-transporter 2 inhibitor in adults with type 2 diabetes using insulin","author":"Woo","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.dsx.2019.04.041_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes \u2013 a systematic review","author":"R\u00e5dholm","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2019.04.041_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose Co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review","author":"Zelniker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.dsx.2019.04.041_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/phar.1903","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes","author":"Trujillo","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.dsx.2019.04.041_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2017.1258401","article-title":"Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes","author":"Tomlinson","year":"2017","journal-title":"Expert Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.dsx.2019.04.041_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-016-0822-7","article-title":"Implications of the EMPA-REG trial for clinical care and research","author":"Stamatouli","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.dsx.2019.04.041_bib51","doi-asserted-by":"crossref","DOI":"10.2174\/1381612823666170519144841","article-title":"Effects of oral and non-insulin injectable antidiabetic treatment in hypertension: a systematic review","author":"Katsi","year":"2017","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.dsx.2019.04.041_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0575-x","article-title":"Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis","author":"Gautam","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2019.04.041_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.dsx.2019.04.041_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2017.05.009","article-title":"Pharmacologic management of type 2 diabetes mellitus: available therapies","author":"Thrasher","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.dsx.2019.04.041_bib55","article-title":"The kidney and cardiovascular outcome trials","author":"Bloomgarden","year":"2018","journal-title":"J\u00a0Diabetes"},{"key":"10.1016\/j.dsx.2019.04.041_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(17)30259-0","article-title":"SGLT2 inhibitors in the real world: too good to be true?","author":"Fitchett","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.dsx.2019.04.041_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3124","article-title":"Cardiovascular effects of SGLT-2 inhibitors: what we have learned from cardiovascular outcome trials and what we still need to understand","author":"Cavallari","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.dsx.2019.04.041_bib58","first-page":"1","article-title":"The SGLT2 inhibitor empagliflozin might Be a new approach for the prevention of acute kidney injury","author":"Chu","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.dsx.2019.04.041_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2016.02.134","article-title":"Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies","author":"Ghosh","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.dsx.2019.04.041_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13612","article-title":"How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study","author":"Birkeland","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2019.04.041_bib61","first-page":"1","article-title":"Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?","author":"Raschi","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dsx.2019.04.041_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2018.01.012","article-title":"The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)\u2013TIMI 58 trial","author":"Wiviott","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.dsx.2019.04.041_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.11.010","article-title":"Can we DECLARE a victory against cardio-renal disease in diabetes?","author":"Connelly","year":"2018","journal-title":"Cell Metabol"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402119302504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402119302504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:08:05Z","timestamp":1761728885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402119302504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1871402119302504"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2019.04.041","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are SGLT2 inhibitors joining the mainstream therapy for diabetes type\u00a02?","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2019.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}